Physician profile
Gary D Garrett
NPI 1932158581
$2,373.28
in general payments reported to CMS, 2019-2025
23 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $175 · 2021: $27.05 · 2022: $70.07 · 2023: $363 · 2024: $570 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $372.13 | 2019-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $255.23 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $254.99 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $216.15 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Amarin Pharma, INC. | $206.99 | 2019-2021 | |
| Glaxosmithkline, LLC. | $131.41 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Abbott Laboratories | $128.95 | 2023-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $123.42 | 2022-2023 | |
| Lilly USA, LLC | $120.87 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Exact Sciences Corporation | $113.88 | 2023-2024 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $87.34 | 2019-2024 | Heplisav-B |
| Jazz Pharmaceuticals INC. | $62.01 | 2019-2020 | |
| Dexcom, INC. | $61.50 | 2023-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $48.88 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $39.50 | 2019-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $32.71 | 2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $21.05 | 2024 | |
| Allergan, INC. | $20.43 | 2020 | |
| Genentech USA, INC. | $18.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.36 | 2019 | |
| Amgen INC. | $15.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.54 | 2019 | |
| Esperion Therapeutics, INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Garrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.